Biotech Values

[DewDiligence]

OXGN revises phase-2/3 plans for Fosbretabulin (a/k/a CA4P):

http://finance.yahoo.com/news/oxigene-announces-plans-advance-ca4p-200500900.html

OXiGENE's advancement plans include two phase 2/3 clinical trials evaluating whether CA4P improves the current standard-of-care in patients who have failed to respond to initial treatment. Both trials planned by the company are designed as two stage, phase 2/3 studies. The first stage of each trial would be a randomized, investigator-blinded, placebo-controlled study with up to 80 patients. The second stage of each trial would be a large, double-blind, placebo-controlled, confirmatory phase 3 study, the start of which would be triggered by a demonstration of efficacy in the first stage.

…The first clinical trial OXiGENE plans to initiate will be in platinum-resistant ovarian cancer, with the goal of determining whether the addition of CA4P to the standard-of-care (chemotherapy plus Avastin (bevacizumab)) improves patient outcomes. Patients would be randomized on a 1:1 basis to receive either the current standard-of-care or the current standard-of-care plus CA4P. The primary endpoint will be progression-free survival (PFS). The company expects to initiate the trial in the first half of 2016.

…The second phase 2/3 clinical trial OXiGENE plans to initiate will be in glioblastoma multiforme (GBM) patients who have failed first-line chemotherapy treatment, with the goal of determining whether CA4P improves upon the current standard of care, which is treatment with Avastin(R) alone. Patients will be randomized on a 1:1 basis to receive either Avastin(R) or Avastin plus CA4P. The primary endpoint will be PFS. The company expects to initiate the trial in the second half of 2016.

CC tomorrow at 9am ET.